Industry News
Resistance In Melanoma Patients Delayed By Combination Of Targeted Treatment Drugs
Oct 02, 2012
Combined treatment with two drugs targeting different points in the same growth-factor pathway delayed the development of treatment resistance in patients with BRAF-positive metastatic malignant melanoma... Read More
Drug Trials Seek Combinations Effective For Melanoma
Oct 02, 2012
Promising new data from trials aimed at delaying resistance to BRAF inhibitors Promising new data on drug combinations to treat metastatic melanoma were presented at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna... Read More
Subcutaneous VELCADE® Approved In The EU For The Treatment Of Multiple Myeloma
Oct 02, 2012
Janssen-Cilag International NV (Janssen) has announced that the European Commission has granted marketing authorisation for the subcutaneous (under the skin) administration of VELCADE® (bortezomib) in the European Union. Bortezomib is indicated for the treatment of multiple myeloma, a type of blood cancer... Read More
In MISSION Trial Sorafenib Not Found To Extend Overall Survival As Third Or Fourth Line Therapy In Lung Cancer
Oct 02, 2012
Phase III MISSION trial - EGFR status may help select patients who will benefit most Treatment with the drug sorafenib as a third or fourth line therapy does not result in improved overall survival among patients with advanced non-small cell lung cancer (NSCLC), according to findings released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna... Read More
Investigational Brain Cancer Vaccine To Be Tested In Phase I Roswell Park Study
Oct 02, 2012
A new clinical research study at Roswell Park Cancer Institute (RPCI) will test a first-of-its-kind cancer "vaccine" that may prove effective against many forms of solid-tumor cancers... Read More
Physicians Identify Reasons For High Cost Of Cancer Drugs, Prescribe Solutions
Oct 02, 2012
A virtual monopoly held by some drug manufacturers in part because of the way treatment protocols work is among the reasons cancer drugs cost so much in the United States, according to a commentary by two Mayo Clinic physicians in the October issue of the journal Mayo Clinic Proceedings. Value-based pricing is one potential solution, they write... Read More
Use Of Interstitial Fluid Pressure Via Noninvasive Measurement, A Potential Biomarker For Tumor Aggressiveness
Oct 02, 2012
Researchers validated a method of noninvasive imaging that provides valuable information about interstitial fluid pressure of solid tumors and may aid in the identification of aggressive tumors, according to the results of a study published in Cancer Research, a journal of the American Association for Cancer Research... Read More
Key Mechanism Discovered For Controlling The Body's Inflammatory Response
Oct 02, 2012
Researchers at Queen Mary, University of London have discovered how a key molecule controls the body's inflammatory responses. The molecule, known as p110delta, fine-tunes inflammation to avoid excessive reactions that can damage the organism. The findings, published in Nature Immunology, could be exploited in vaccine development and new cancer therapies... Read More
Advances In Esophageal And Gastrointestinal Cancer Treatments
Oct 02, 2012
New trial data showing improvements in the treatment of esophageal and gastrointestinal cancers were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna... Read More
Breast Cancer Recurrence Defined By Hormone Receptor Status
Oct 02, 2012
Human epidermal growth factor (HER2) positive breast cancers are often treated with the same therapy regardless of hormone receptor status... Read More
Previous Page Next Page